logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 12 of 12 Items
Showing 1 - 12 of 12 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: A multicentric retrospective cohort study

Singla R, Khan S, Silsarma A, Chavan V, Mahajan R,  et al.
2025-03-13 • Clinical Infectious Diseases
2025-03-13 • Clinical Infectious Diseases

BACKGROUND

Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. Th...

Journal Article
|
Letter

Sustained treatment success at 12 months for drug-resistant TB patients on concomitant bedaquiline-delamanid

Chavan V, Silsarma A, Mahajan R, Khan S, Singh P,  et al.
2025-02-01 • IJTLD OPEN
2025-02-01 • IJTLD OPEN
Conference Material
|
Poster

12-month post-treatment outcomes of previously treated drug-resistant tuberculosis patients subsequently treated with concomitant bedaquiline and delamanid +/-carbapenem, in Mumbai, India

Chavan V, Silsarma A, Khan S, Singh P, Iyer A,  et al.
2024-11-08 • MSF Scientific Days Asia 2024
2024-11-08 • MSF Scientific Days Asia 2024
Journal Article
|
Research

Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India

Mongia H, Mamnoon F, Silsarma A, Mahajan R, Dalal A,  et al.
2024-04-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
2024-04-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
BACKGROUND
World Health Organization suggests concurrent bedaquiline-delamanid (BDQ-DLM) as part of individualised regimens for eligible patients with pulmonary drug-resistant tuberc...
Conference Material
|
Poster

Treatment outcomes among drug-resistant children below 10 years treated with newer drugs, in Médecins Sans Frontieres clinic in Mumbai, India

Singh SN, Singh P, Silsarma A, Iyer AS, Galindo MA,  et al.
2022-11-30 • MSF Paediatric Days 2022
2022-11-30 • MSF Paediatric Days 2022
Journal Article
|
Research

Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges

Chavan VV, Dalal A, Nagaraja SB, Thekkur P, Mansoor H,  et al.
2020-06-16 • PLOS One
2020-06-16 • PLOS One
Background
Imipenem, an intravenous antibiotic is recommended for use in drug resistant tuberculosis (DR-TB) when an effective regimen with combination of other second line drugs is...
Journal Article
|
Research

Routine viral load monitoring and enhanced adherence counselling at a public ART centre in Mumbai, India

Laxmeshwar C, Acharya S, Das M, Keskar P, Pazare A,  et al.
2020-05-05 • PLOS One
2020-05-05 • PLOS One
BACKGROUND
Routine viral-load (VL) measurements along with enhanced adherence counselling (EAC) are recommended to achieve virological suppression among people living with HIV/AIDS (...
Journal Article
|
Research

Yield of systematic longitudinal screening of household contacts of pre-extensively drug resistant (PreXDR) and extensively drug resistant (XDR) tuberculosis patients in Mumbai, India

Paryani R, Gupta V, Singh P, Verma M, Sheikh S,  et al.
2020-05-26 • Tropical Medicine and Infectious Disease
2020-05-26 • Tropical Medicine and Infectious Disease
While risk of tuberculosis (TB) is high among household contacts (HHCs) of pre-extensively drug resistant (pre-XDR) TB and XDR-TB, data on yield of systematic longitudinal screening are ...
Journal Article
|
Research

One step forward: successful end-of-treatment outcomes of patients with drug-resistant tuberculosis who received concomitant bedaquiline and delamanid in Mumbai, India

Das M, Dalal A, Laxmeshwar C, Ravi S, Mamnoon F,  et al.
2021-11-02 • Clinical Infectious Diseases
2021-11-02 • Clinical Infectious Diseases
BACKGROUND
The Médecins Sans Frontières clinic in Mumbai, India, has been providing concomitant bedaquiline (BDQ) and delamanid (DLM) in treatment regimen for patients with drug-resi...
Conference Material
|
Poster

Treatment outcomes of bedaquiline-exposed tuberculosis patients treated with a regimen containing bedaquiline and delamanid: findings from MSF clinic, Mumbai, India

Mongia H, Mansoor H, Mamnoon F, Silsarma A, Davuluri P,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
No abstract available.
Journal Article
|
Research

One step forward: Successful end-of-treatment outcomes of drug-resistant TB patients who received concomitant bedaquiline and delamanid in Mumbai, India

Das M, Dalal A, Laxmeshwar C, Ravi S, Mamnoon F,  et al.
2020-10-20 • Clinical Infectious Diseases
2020-10-20 • Clinical Infectious Diseases
Background
Médecins Sans Frontières clinic in Mumbai, India has been providing concomitant Bedaquiline (BDQ) and Delamanid (DLM) in treatment regimen for patients with drug-resistan...
Journal Article
|
Research

New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India

Das M, Mamnoon F, Mansoor H, Meneguim A, Singh P,  et al.
2020-12-01 • International Journal of Tuberculosis and Lung Disease
2020-12-01 • International Journal of Tuberculosis and Lung Disease
SETTING: Médecins Sans Frontières (MSF) clinic in Mumbai, India.

OBJECTIVE: To determine the final treatment outcomes, culture conversion and adverse events (AEs) during treat...